Abatacept Versus Adalimumab Head-to-Head
A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Cordoba, Argentinien, 5000
- Local Institution
-
San Juan, Argentinien, 5400
- Local Institution
-
Tucuman, Argentinien, 4000
- Local Institution
-
-
Buenos Aires
-
Ciudad Autonoma, Buenos Aires, Argentinien, CP1425A WC
- Local Institution
-
Ciudad Autonoma De Beunos Aire, Buenos Aires, Argentinien, 1431
- Local Institution
-
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentinien, 1015
- Local Institution
-
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentinien, C1428DQG
- Local Institution
-
Quilmes, Buenos Aires, Argentinien, 1878
- Local Institution
-
-
Cordoba
-
Cordoba, Crd, Cordoba, Argentinien, X5016KEH
- Local Institution
-
-
Santa Fe
-
Rosario, Santa Fe, Argentinien, 2000
- Local Institution
-
-
Tucuman
-
San Miguel De Tucuman, Tucuman, Argentinien, 4000
- Local Institution
-
-
-
-
Providencia
-
Santiago, Providencia, Chile
- Local Institution
-
-
-
-
-
Quebec, Kanada, G1V 3M7
- Local Institution
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3A 1M3
- Local Institution
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 1Y2
- Local Institution
-
-
Quebec
-
Trois-Rivieres, Quebec, Kanada, G8Z 1Y2
- Local Institution
-
-
-
-
-
Lima, Peru
- Local Institution
-
Lima, Peru, LIMA 11
- Local Institution
-
Lima, Peru, LIMA 33
- Local Institution
-
Lima, Peru, LIMA 27
- Local Institution
-
-
Callao 2
-
Bellavista, Callao 2, Peru
- Local Institution
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- University of Alabama at Birmingham
-
Birmingham, Alabama, Vereinigte Staaten, 35205
- Rheumatology Associates, Pc
-
Tuscaloosa, Alabama, Vereinigte Staaten, 35406
- Clinical and Translational Research Center of Alabama, PC
-
-
Arizona
-
Peoria, Arizona, Vereinigte Staaten, 85381
- Sun Valley Arthritis Center, Ltd.
-
-
Arkansas
-
Hot Springs, Arkansas, Vereinigte Staaten, 71913
- Mercy Clinic Hot Springs Communities
-
-
California
-
Huntington Beach, California, Vereinigte Staaten, 92646
- Talbert Medical Group
-
La Jolla, California, Vereinigte Staaten, 92037
- Allergy & Rheumatology Medical Clinic, Inc.
-
Long Beach, California, Vereinigte Staaten, 90806
- Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
-
Pasadena, California, Vereinigte Staaten, 91107
- Irene Y. Tong
-
San Diego, California, Vereinigte Staaten, 92108
- San Diego Arthritis Medical Clinic
-
Torrance, California, Vereinigte Staaten, 90503
- Healthcare Partners Medical Group
-
Torrance, California, Vereinigte Staaten, 90505
- Drs. Goldin, Nies, Klashman & Eng
-
Upland, California, Vereinigte Staaten, 91786
- Inland Rheumatology & Osteoporosis Medical Group
-
-
Florida
-
Aventura, Florida, Vereinigte Staaten, 33180
- Arthritis and Rheumatic Disease Specialties
-
Gainesville, Florida, Vereinigte Staaten, 32610
- University Of Florida College Of Medicine At Jacksonville
-
Miami, Florida, Vereinigte Staaten, 33173
- Center for Arthritis and Rheumatic Diseases
-
Palm Harbor, Florida, Vereinigte Staaten, 34684
- Arthritis Research Of Florida, Inc.
-
Sarasota, Florida, Vereinigte Staaten, 34239
- Sarasota Arthritis Research Center
-
South Miami, Florida, Vereinigte Staaten, 33143
- Miami Research Associates
-
Tamarac, Florida, Vereinigte Staaten, 33321
- West Broward Rheumatology Associates
-
Venice, Florida, Vereinigte Staaten, 34292
- Lovelace Scientific Resources, Inc
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Arthritis & Rheumatology of Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Laureate Clinical Research Group
-
Gainesville, Georgia, Vereinigte Staaten, 30501
- Arthritis Center of North Georgia
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83702
- St. Luke's Clinic - Rheumatology
-
Coeur D Alene, Idaho, Vereinigte Staaten, 83814
- Coeur D'Alene Arthrit Clin
-
-
Illinois
-
Quincy, Illinois, Vereinigte Staaten, 62301
- Quincy Medical Group
-
Rockford, Illinois, Vereinigte Staaten, 61107
- Rockford Orthopedic Associates, Ltd.
-
-
Iowa
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52401
- Physicians Clinic of Iowa
-
-
Kentucky
-
Elizabethtown, Kentucky, Vereinigte Staaten, 42701
- Center For Arthritis and Osteoporosis
-
Lexington, Kentucky, Vereinigte Staaten, 40504
- Bluegrass Community Research, Inc.
-
-
Maryland
-
Cumberland, Maryland, Vereinigte Staaten, 21502
- Klein And Associates, M.D., Pa
-
Wheaton, Maryland, Vereinigte Staaten, 20902
- The Center For Rheumatology And Bone Research
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Brigham and Women's Hospital
-
Mansfield, Massachusetts, Vereinigte Staaten, 02048
- Mansfield Health Center
-
-
Michigan
-
Battle Creek, Michigan, Vereinigte Staaten, 49015
- Associated Internal Medicine Specialists
-
Kalamazoo, Michigan, Vereinigte Staaten, 49009
- Rheumatology Pc
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39202
- Arthritis Associates Of Mississippi
-
-
Missouri
-
St.Louis, Missouri, Vereinigte Staaten, 63131
- Physician Groups, Lc Dba
-
-
Nevada
-
Reno, Nevada, Vereinigte Staaten, 89502
- Arthritis Center of Reno
-
-
New Hampshire
-
Dover, New Hampshire, Vereinigte Staaten, 03820
- Seacoast Arthritis And Osteoporosis Center
-
Nashua, New Hampshire, Vereinigte Staaten, 03060
- Nashua Rheumatology
-
-
New Mexico
-
Las Cruces, New Mexico, Vereinigte Staaten, 88011
- Arthritis and Osteoporosis Associates of New Mexico
-
-
New York
-
Lake Success, New York, Vereinigte Staaten, 11042
- North Shore Lij Health System
-
Mineola, New York, Vereinigte Staaten, 11501
- Winthrop University Hospital
-
Smithtown, New York, Vereinigte Staaten, 11787
- Rheumatology Associates of Long Island
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28803
- Asheville Rheumatology & Osteoporosis Research Asso P. A.
-
Statesville, North Carolina, Vereinigte Staaten, 28625
- Carolina Pharmaceutical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73109
- Health Research Institute
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73103
- Health Research of Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73112
- Lynn Health Sciences Institute
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
- East Penn Rheumatology Associates, P.C.
-
Duncansville, Pennsylvania, Vereinigte Staaten, 16635
- Altoona Center for Clinical Research
-
Wyomissing, Pennsylvania, Vereinigte Staaten, 19610
- Clinical Research Center of Reading, LLP
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29406
- Low Country Rheumatology, PA
-
Columbia, South Carolina, Vereinigte Staaten, 29204
- Columbia Arthritis Center, P.A.
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78758
- Lovelace Scientific Resources, Inc.
-
Dallas, Texas, Vereinigte Staaten, 75246
- Arthritis Centers Of Texas
-
Houston, Texas, Vereinigte Staaten, 77004
- Rheumatic Disease Clinical Research Center, LLC
-
-
Virginia
-
Chesapeake, Virginia, Vereinigte Staaten, 23320
- Center For Arthritis & Rheumatic Diseases, Pc
-
-
Washington
-
Spokane, Washington, Vereinigte Staaten, 99202
- Rockwood Research Center
-
-
West Virginia
-
Clarksburg, West Virginia, Vereinigte Staaten, 26301
- Mountain State Clinical Research
-
-
Wisconsin
-
Glendale, Wisconsin, Vereinigte Staaten, 53217
- Rheumatic Disease Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria
- Methotrexate failure
- Naive to RA biologics
- ≤5 years duration of disease
- Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2
- Willingness to self-inject subcutaneous (SC) drug
Exclusion Criteria:
- Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents
- History of active or chronic hepatitis
- Cancer in the last 5 years
- History of severe chronic or recurrent bacterial or viral infections
- Risk of tuberculosis
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Adalimumab
|
Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
Andere Namen:
|
|
Aktiver Komparator: Abatacept
|
Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population
Zeitfenster: Day 1 to Day 365
|
Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N).
The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage.
To qualify a ACR20 score, patient must have >=20% fewer tender joints and >=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein (CRP) test (to assess inflammation).
Baseline was Day 1. Randomization was stratified using screening Disease Activity Score-28 (DAS28) CRP, a composite of 4 variables: number of tender joints/28, number of swollen joints/28, CRP in mg/L and participant assessment of disease activity with visual analogue scale.
|
Day 1 to Day 365
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population
Zeitfenster: Day 1 to 12 Months
|
n=number of participants with a pre-specified local injection site reaction event, N=number of participants at risk.
Proportion (%) = n/N.
12 Months includes data up to 56 days post last dose of the first 12 months Period or start of the first dose of second 12 months period.
|
Day 1 to 12 Months
|
|
Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population
Zeitfenster: Day 1 to Day 729
|
Incidence Rate: (incidence/100 person-years) = number of participants with event * 100 /exposure (person-years) Exposure (person-years) = the sum over all participants of the exposure per participant in the 24 months (censored at the time of first occurrence of AE) expressed in days, divided by 365.25.
The 24 Month Period includes data up to 56 days post the last dose in the 24 month period.
Poisson distribution used to construct the 95% CIs.
|
Day 1 to Day 729
|
|
Proportion of Participants Without Radiographic Progression in Total Score Less Than or Equal to the Smallest Detectable Change (SDC) From Baseline to Months 12 and 24 Using Modified Van Der Heijde Total Sharp Score (mSvdHS) - ITT Population
Zeitfenster: Baseline to Day 729
|
Plain radiographs of hands and feet taken at baseline (BL), Day 365, and Day 729.
BL and Day 365 radiographs were re-read concurrent with Day 729 films by readers blinded to sequence and treatment (a second pre-specified reading campaign).
SDC defined as amount of change for which anything smaller could not be reliably distinguished from random error in measurement of simultaneously read films.
Non-progression defined: change from BL (Day 1, prior to dosing) in total score less than, equal to (<=) SDC(2.2).
Proportion n/m (%)=number meeting criteria (n); number analyzed (m).
SDC calculated as SD/sqrt(2)*1.96/sqrt(2)with
standard deviation (SD) of paired differences of change from BL in total score between 2 readers; squared root(sqrt).
mSvdHS=summary of erosion severity in 32 hand and 12 foot joints.
Hand joints scored 0 to 5; foot joints 0 to 10 with 0=no erosion and higher numbers indicating greater erosion severity.
BL: radiographic data within 14 days or less of first dose.
|
Baseline to Day 729
|
|
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 12 Months of Treatment - ITT Population
Zeitfenster: Day 1 to Day 365
|
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, all hospitalized infections.
Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post-last dose of first 12 months or start of first dose of second 12 months); denominator was overall total exposure (person-years) within this period, calculated as sum over all participants of exposure (in days) divided by 365.25.
The resulting incidence rate was multiplied by 100 to express rate per 100 person-years.
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
|
Day 1 to Day 365
|
|
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 24 Months of Treatment - ITT Population
Zeitfenster: Day 1 to Day 729
|
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, and all hospitalized infections.
Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post the last dose of the 24 Months period); denominator was overall total exposure (person-years) within this period, which was calculated as the sum over all participants of exposure (in days) divided by 365.25.
The resulting incidence rate was multiplied by 100 to express the rate per 100 person-years.
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
|
Day 1 to Day 729
|
|
Proportion of Participants With Induction of Autoantibodies During the 12 Months and 24 Months Periods - ITT Population
Zeitfenster: Day 1 to Day 729
|
The induction of autoantibodies was defined as participant's antinuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) converting from a negative status at baseline to a positive status at a post-baseline measurement time point (Day 365 or Day 729).
Proportion (%) = n/m, where n=number of participants with positive ANA or dsDNA at a time point and m=number of participants who had negative ANA or dsDNA at baseline.
Blood samples were first tested for ANA by indirect fluorescent assay using HEp-2 Cell Line Substrate, and when positive, samples were further tested for anti-dsDNA by indirect fluorescent assay using Crithidia Luciliae Substrate.
|
Day 1 to Day 729
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Keystone EC, Ahmad HA, Yazici Y, Bergman MJ. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford). 2020 Aug 1;59(8):2090-2098. doi: 10.1093/rheumatology/kez455.
- Jabado O, Maldonado MA, Schiff M, Weinblatt ME, Fleischmann R, Robinson WH, He A, Patel V, Greenfield A, Saini J, Galbraith D, Connolly SE. Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. Rheumatol Ther. 2022 Apr;9(2):391-409. doi: 10.1007/s40744-021-00404-x. Epub 2021 Dec 8.
- Fleischmann R, Weinblatt M, Ahmad H, Maldonado MA, Alemao E, Ye J, Schiff M. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatol Ther. 2019 Dec;6(4):559-571. doi: 10.1007/s40744-019-00174-7. Epub 2019 Oct 22.
- Fleischmann R, Connolly SE, Maldonado MA, Schiff M. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. Arthritis Rheumatol. 2016 Sep;68(9):2083-9. doi: 10.1002/art.39714.
- Schiff M, Weinblatt ME, Valente R, Citera G, Maldonado M, Massarotti E, Yazici Y, Fleischmann R. Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open. 2016 Apr 19;2(1):e000210. doi: 10.1136/rmdopen-2015-000210. eCollection 2016.
- Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, Furst DE. Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jul;68(7):907-13. doi: 10.1002/acr.22763.
- Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016 Apr;75(4):709-14. doi: 10.1136/annrheumdis-2015-207942. Epub 2015 Sep 10.
- Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 Jan;73(1):86-94. doi: 10.1136/annrheumdis-2013-203843. Epub 2013 Aug 20.
- Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Autoimmunerkrankungen
- Gelenkerkrankungen
- Erkrankungen des Bewegungsapparates
- Rheumatische Erkrankungen
- Bindegewebserkrankungen
- Arthritis
- Arthritis, Rheuma
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Entzündungshemmende Mittel
- Antirheumatika
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Immun-Checkpoint-Inhibitoren
- Adalimumab
- Abatacept
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IM101-235
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .